Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.
about
Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferretsCharacterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza virusesRisk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivirInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceTreatment of influenza with neuraminidase inhibitors: virological implicationsRWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenzaComparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivirRescue of a H3N2 influenza virus containing a deficient neuraminidase protein by a hemagglutinin with a low receptor-binding affinityResistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol.An overview of the characteristics of the novel avian influenza A H7N9 virus in humans.Isolation and genetic characterization of H5N2 influenza viruses from pigs in Korea.Zanamivir-resistant influenza viruses with a novel neuraminidase mutationAntiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitorsDetection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birdsFluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals.Antiviral strategies for pandemic and seasonal influenzaPandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitorNeuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.Combining crystallographic information and an aspherical-atom data bank in the evaluation of the electrostatic interaction energy in an enzyme-substrate complex: influenza neuraminidase inhibitionSmall interfering RNA targeting m2 gene induces effective and long term inhibition of influenza A virus replication.Dose-dependent changes in influenza virus-infected dendritic cells result in increased allogeneic T-cell proliferation at low, but not high, doses of virus.Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies.Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virusFrequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.Neurovirulence in mice of H5N1 influenza virus genotypes isolated from Hong Kong poultry in 2001Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivirCompetitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium
P2860
Q27314689-64C35EA5-0DAA-45A2-9B85-6FA386D85914Q27680477-A975F28A-A156-4776-AC56-61BF42C96F7FQ28066861-21E0E0DA-7DBC-453D-8E37-D2FF46C638BAQ28282405-3EE3EA0C-CE8A-4752-B5FD-B78CA7EF2327Q28344588-BD2E526B-A257-433A-A908-0A13E183E7FEQ28344592-D052E7BC-D37F-4DB6-B339-31C25D0A51A6Q28364114-A2C169DF-96CE-4BCA-8C50-875B8BF783A0Q28369317-2AB2548E-DD32-4F41-A6A1-9292F95135C2Q28535274-CAF655F2-A985-4283-94A0-7FA58508A24DQ28730182-A9637623-CB3E-4DB2-8549-F204EAF09B3DQ30151772-7BE2F321-9176-46E0-AD96-92425BE1FE38Q30364619-643123C1-60C1-4A21-84F2-A75A0F252450Q30371242-CF0B2DEC-8FC4-4DC2-96D6-A100CDDD2AA4Q30372931-FAD08085-9FB0-4DC4-B0FF-A892676E2803Q30376086-6A423C7F-C851-4E9E-8F9E-067EF6912481Q30379353-F798C3A9-D5FA-4B2E-B485-AC0BAF5B0C88Q30391856-E3E4F998-3BBC-437D-B8EF-C8C9DCD765ACQ30397253-BB4A7422-F3DE-42D6-AFEF-4DCE51859B12Q30398804-FFA4A76E-9409-40D1-A08B-472397D13FC7Q30401424-23608427-475A-4644-9C69-E4914BE19633Q30408116-EEEB9858-B0A4-45B1-B62A-42AF65E32FC1Q30424185-27F7BDC8-E484-4FA7-9877-941D0762F58BQ30438502-AAF6E1CB-9604-45A9-9407-FA69984CEF3CQ30448118-1750FCA6-4CA1-4CBF-9494-14E973E388BDQ30452889-E2E66D13-F411-4655-A633-AFFA98F67409Q30453278-95BC850C-BC7E-48F4-8F94-5123361981BAQ33434347-C05814A9-BA49-4305-B47F-E550A6E48A56Q33455759-DCD0DD36-BFD0-455B-B4F3-8572D61C7658Q33805469-D5151981-B192-4A7D-84F9-7C163E1F48D1Q33826384-839B4FED-E3D9-4C93-AA08-0301A8D95A8DQ33842791-84569B5D-9FC2-4B3B-B53C-FB47CD27B943Q33978456-0098E6AE-E5FD-4269-9DC8-4C08421276EAQ34077100-2440FE1D-FCC8-465B-A096-39008B4F5F6CQ34120005-EDC7A5C3-6758-4E33-A775-5D05A7B34652Q34405859-68FBE3D3-FC6A-426B-AB51-E723A50BADE9Q34678249-E2BAF487-AD29-45C4-982E-A6AE3B2A3B77Q34706374-C365C24B-3DDC-4A2D-9868-557CACB44D29Q34743199-70EBC71C-EA99-41DB-B5FB-7ED2B871C808Q35005209-EB02E6CE-E560-4BAE-8F18-B332125BDBF0Q35640944-BF839A28-CED2-42C2-B0DF-D2CC436A8427
P2860
Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Catalytic and framework mutati ...... tant to 4-guanidino-Neu5Ac2en.
@ast
Catalytic and framework mutati ...... tant to 4-guanidino-Neu5Ac2en.
@en
type
label
Catalytic and framework mutati ...... tant to 4-guanidino-Neu5Ac2en.
@ast
Catalytic and framework mutati ...... tant to 4-guanidino-Neu5Ac2en.
@en
prefLabel
Catalytic and framework mutati ...... tant to 4-guanidino-Neu5Ac2en.
@ast
Catalytic and framework mutati ...... tant to 4-guanidino-Neu5Ac2en.
@en
P2093
P2860
P1433
P1476
Catalytic and framework mutati ...... stant to 4-guanidino-Neu5Ac2en
@en
P2093
L V Gubareva
M J Robinson
R C Bethell
P2860
P304
P407
P577
1997-05-01T00:00:00Z